Luminary Award

The PMWC Luminary Award is honoring a figure whose leadership has significantly contributed over the years to the advancement and one of the many aspects of patient-centric healthcare, therefore shaping what is known today as precision medicine.

Janet Woodcock

Brian Druker

George Church

Contributions to the sequencing of genomes and interpreting such data; In Neuroscience he established a “functional connectome”

Lee Hood

2010

Inventions included the automated DNA sequencer and a tool for synthesizing DNA

Award Recipients: Duke

Francis S. Collins

2017

Advancing Precision Medicine by Leading Sequencing of the Human Genome and Other Major Government Initiatives

Elaine R. Mardis

2017

Sequencing Technologies Visionary and Leader in Genomics and Cancer Genomics

Keith R. Yamamoto

2017

Conception, Implementation and Advocacy for Precision Medicine

Pioneer Award

The PMWC Pioneer Award is given on occasion to a rare individual who presaged the present day excitement regarding personalized medicine, and, at a time when technology wasn’t as evolved and less peer encouragement existed, nevertheless, made substantial contributions to the field.

Kim Popovits

Award Recipients: UK

Jonathan K.C. Knowles

Personalized Medicine Leader in both Academia and the Pharmaceutical Industry

Award Recipients: Duke

Kathy Giusti

2017

Pioneer in Business Leadership to Advance Life-Saving Therapies and Institutional Collaboration

Mark Levin

2017

Advances Personalized Medicine Through His Business, Science and Policy Acumen

Most Promising Company Award

The PMWC Most Promising Company Competition has accompanied PMWC since 2009 with the goal to assist “rising star” startups in Diagnostics, Therapeutics, and Health Tech to increase their visibility, provide them with a platform to present to a group of leading investors, as well as to potential clients and partners so they can succeed on their path forward.

Two Pore Guys

Two Pore Guys created a solid-state nanopore-based diagnostic testing platform that can detect nucleic acids, proteins and other analytes with comparable performance of lab equipment, in a glucometer-style system.
Website: twoporeguys.com

HEALTHMYNE

HealthMyne is an imaging informatics company dedicated to transforming patient care by enabling image data mining within the clinical workflow. Built on an FDA-cleared diagnostic platform, HealthMyne tools will increase radiologist efficiency by automating both data capture and structured reports.
Website: healthmyne.com

INSILICO MEDICINE

Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases.
Website: insilicomedicine.com

ACCEL DIAGNOSTICS

AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests at any time and any place. The patented pScreen™ platform technology employs a single-use blood test the size of a credit card in tandem with a smartphone application to quickly detect disease-specific biomarker levels.
Website: acceldx.com

T2 BIOSYSTEMS

T2 Biosystems is an in vitro diagnostics company that has developed an innovative and proprietary technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. Their new class of clinical diagnostics powered by T2MR is the world’s first direct detection technology that delivers superior sensitivity at unmatched speed to guide more effective clinical decision-making. IPO, Aug. 2014.
Website: t2biosystems.com

ELMINDA

ElMindA has developed the BNA™ technology platform, which for the first time allows high resolution visualization and evaluation of the complex neuro-physiological interconnections of the human brain at work, capturing information on the composition, connectivity, synchronization and operation of brain networks.
Website: elminda.com

HORIZON DISCOVERY

Horizon Discovery Limited has developed a translational genomics platform and drug discovery toolbox that enables the development of new therapies targeted at the genetic features that drive an individual’s cancer. IPO, March 2014.
Website: horizondiscovery.com

QUANTALIFE

QuantaLife provides advanced genetic analysis systems for research. QuantaLife has commercialized the Droplet Digital™ (ddPCR) system, the most accurate genetic analysis platform available today. The system is the first cost-effective, high-resolution platform available for the validation of next-generation sequencing discoveries. With the ddPCR system, researchers can explore complex genetic landscapes in high-definition, discover new disease associations, and define a new category of improved molecular diagnostic tests. Acquired by Bio-Rad, October 2011.
Website: bio-rad.com

APPLIED IMMUNE TECHNOLOGIES

Applied Immune Technologies’ (AIT) core technology platforms encompass the identification and validation of novel MHC-based targets, as well as development of therapeutic Human Recombinant T-Cell Receptor-Like (TCRL) antibodies with the unique ability to bind with these intracellular peptide/MHC complexes with the specificity of cytotoxic T-cell killer cells. Acquired by Adicet Bio, January 2016. Website: tcrl.co.il